people
(Distinguished Professor Sang Yup Lee)
Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering was re-appointed as the co-chair of the Global Future Council on Biotechnology at the World Economic Forum during the annual GFC meeting in Dubai, UAE last week. Elizabeth O’Day, founder and CEO of Olaris Therapeutics, will co-chair the council with him for two years.
Professor Lee served as the inaugural co-chair of the council for two years from 2016 with Professor Feng Zhang from the Broad Institute of MIT and Harvard.
The World Economic Forum’s Global Future Councils on Biotechnology is comprised of 14 members and aims to identify policy opportunities to help accelerate new biotechnological discoveries and applications while guiding dialogue with consumers about their implications.
Professor Lee, who has made significant research breakthroughs in the field of systems metabolic engineering, received the George Washington Carver Award, the PV Danckwerts Memorial Lecture Award, and the Eni Award this year.
-
event Professor Mikyoung Lim from Mathematical Sciences to Deliver Keynote at International Conference on Applied Inverse Problems
<Professor Mikyoung Lim from KAIST Department of Mathematical Sciences> Professor Mikyoung Lim from KAIST Department of Mathematical Sciences gave a plenary talk on "Research on Inverse Problems based on Geometric Function Theory" at AIP 2025 (12th Applied Inverse Problems Conference). AIP is one of the leading international conferences in applied mathematics, organized biennially by the Inverse Problems International Association (IPIA). This year's conference was held from July 2
2025-08-14 -
event KAIST Takes the Lead in Developing Core Technologies for Generative AI National R&D Project
KAIST (President Kwang Hyung Lee) is leading the transition to AI Transformation (AX) by advancing research topics based on the practical technological demands of industries, fostering AI talent, and demonstrating research outcomes in industrial settings. In this context, KAIST announced on the 13th of August that it is at the forefront of strengthening the nation's AI technology competitiveness by developing core AI technologies via national R&D projects for generative AI led by the Minis
2025-08-13 -
research KAIST develops “FlexGNN,” a graph analysis AI 95 times faster with a single GPU
<(From Left) Donghyoung Han, CTO of GraphAI Co, Ph.D candidate Jeongmin Bae from KAIST, Professor Min-soo Kim from KAIST> Alongside text-based large language models (LLMs) including ChatGPT, in industrial fields, GNN (Graph Neural Network)-based graph AI models that analyze unstructured data such as financial transactions, stocks, social media, and patient records in graph form are being actively used. However, there is a limitation in that full graph learning—training the entire
2025-08-13 -
research KAIST Develops World’s First Wireless OLED Contact Lens for Retinal Diagnostics
<ID-style photograph against a laboratory background featuring an OLED contact lens sample (center), flanked by the principal authors (left: Professor Seunghyup Yoo ; right: Dr. Jee Hoon Sim). Above them (from top to bottom) are: Professor Se Joon Woo, Professor Sei Kwang Hahn, Dr. Su-Bon Kim, and Dr. Hyeonwook Chae> Electroretinography (ERG) is an ophthalmic diagnostic method used to determine whether the retina is functioning normally. It is widely employed for diagnosing hereditary
2025-08-12 -
research KAIST Develops AI That Automatically Designs Optimal Drug Candidates for Cancer-Targeting Mutations
< (From left) Ph.D candidate Wonho Zhung, Ph.D cadidate Joongwon Lee , Prof. Woo Young Kim , Ph.D candidate Jisu Seo > Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) that could bind to that protein and block its function. This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model th
2025-08-12